Westbourne Investment Advisors Inc. increased its stake in Pfizer, Inc. (NYSE:PFE) by 2.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,669 shares of the biopharmaceutical company’s stock after buying an additional 600 shares during the period. Westbourne Investment Advisors Inc.’s holdings in Pfizer were worth $929,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Asset Planning Services Ltd. raised its stake in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the last quarter. D. Scott Neal Inc. increased its position in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the period. Orrstown Financial Services Inc. increased its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the period. Franklin Parlapiano Turner & Welch LLC purchased a new position in shares of Pfizer during the first quarter valued at $121,000. Finally, Cascade Investment Advisors Inc. increased its position in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares during the period. 70.10% of the stock is owned by hedge funds and other institutional investors.
Pfizer, Inc. (NYSE:PFE) traded down 0.51% during mid-day trading on Friday, hitting $33.25. 12,928,473 shares of the company traded hands. The company’s 50-day moving average price is $33.40 and its 200 day moving average price is $33.31. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.38. The company has a market capitalization of $198.43 billion, a price-to-earnings ratio of 24.32 and a beta of 1.00.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. Pfizer’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.64 earnings per share. On average, analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be given a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.85%. Pfizer’s payout ratio is 94.12%.
A number of research analysts have commented on the stock. Berenberg Bank set a $39.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Jefferies Group LLC set a $35.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. UBS AG restated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. Finally, BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $33.00 to $37.00 in a research report on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $37.77.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.